angiotensin-converting enzyme inhibitor + anthracycline

This refers to a combination therapy involving an angiotensin-converting enzyme inhibitor (ACEI) and an anthracycline. ACE inhibitors are a class of small molecule drugs that inhibit the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Anthracyclines are a class of antineoplastic agents (such as doxorubicin or daunorubicin) widely used in cancer chemotherapy, particularly for breast cancer and lymphomas, but are known for their risk of cardiotoxicity. The rationale for combining an ACE inhibitor with an anthracycline is primarily cardioprotection—ACE inhibitors may help prevent or reduce the cardiac dysfunction (e.g., decline in left ventricular ejection fraction) associated with anthracycline chemotherapy by mitigating oxidative stress and adverse ventricular remodeling[1][2][3][5]. This combination is not a fixed-dose pharmaceutical product but rather describes concurrent use as part of supportive care during cancer treatment.